Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 16, 2026, titled "Sentynl Therapeutics Enters into Agreement with PRG S&T to License Molecule for Hutchinson-Gilford Progeria Syndrome".
Press Release Mar 16 2026
Filed with NSE · · 4 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release regarding an agreement between Sentynl Therapeutics and PRG S&T to license a molecule for Hutchinson-Gilford Progeria Syndrome. The agreement allows Sentynl to acquire full rights to the investigational drug candidate Progerinin, which is intended for the treatment of this rare genetic disorder. This licensing deal is part of Sentynl's strategy to expand its portfolio of therapies for rare diseases, specifically targeting progeria. The press release emphasizes the importance of advancing treatments for patients affected by this severe condition.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 14 2026
- Press Release Mar 13 2026
- Press Release Mar 12 2026
- Press Release Feb 28 2026
- Press Release Feb 27 2026
Later from Zydus Lifesciences
- Press Release Mar 17 2026
- Press Release Mar 18 2026
- AeroDel signs exclusive licensing arrangement with Zydus for launching Aerolife Mini™, India's First Foldable, 'Always Attached' pMDI Enhancer
- Press Release Mar 19 2026
- Zydus Lifesciences Limited Press Release Mar 21 2026
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences